Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG)), By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others), By Route of Administration (Oral v/s Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region

August 2023 | 111 pages | ID: U4B22110CE18EN
TechSci Research

Abstracts

The global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches.

Rising Prevalence of urea cycle disorders among the Population

The growing prevalence of urea cycle disorders is likely to propel the growth of the market globally. According to reports published by the Centers for Disease Control and Prevention (CDC), the projected occurrence of urea cycle disorders is 1 in 8500 births. Owing to the many cases which remain undiagnosed and the newborns with the disorders die without a complete diagnosis; the exact numbers remain unknown. It is assumed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be ascribed to an undiagnosed inborn error of metabolism, such as a urea cycle disorder which is anticipated to impel the urea cycle disorders treatment market.

Increasing Initiatives and Awareness Among Patients

Over the past few years, governments of different nations and private organizations have been taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments in research and development, increase in awareness programs, extensive research activities and clinical trials, and ease in approvals by the regulatory bodies are the supporting factors for the market. For instance, in 2017, Mead Johnson Nutrition Company (MJN) declared its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, included its globally recognized brands, incorporating Enfa and Nutramigen, which are used in the dietary management of urea cycle disorder, to RB's consumer health portfolio, thus bolstering its position globally. Similarly, in 2017, Horizon Pharma plc launched UCD in Common, an initiative for individuals suffering from urea cycle disorder, to offer educational, supportive, and interactive resources to the patients residing with UCD, their families, and healthcare specialists.

Market Segmentation

The global urea cycle disorders treatment market is segmented into enzyme deficiency type, treatment type, route of administration, distribution channel, and company. Based on enzyme deficiency type, the market is divided into carbamyl phosphate synthetase (CPS1), N-acetyl glutamate synthetase (NAGS), ornithine transcarbamylase (OTC deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL or ASA lyase), and arginase (AG). Based on treatment type, the market is divided into amino acid formulas, phenylbutyrate, sodium benzoate, and others. Based on the route of administration, the market is divided into oral and intravenous. Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of cases of urea cycle diseases in the country.

Market Players

Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

• Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type:
• Carbamyl Phosphate Synthetase (CPS1)
• N-Acetylglutamate Synthetase (NAGS)
• Ornithine Transcarbamylase (OTC Deficiency)
• Argininosuccinic Acid Synthetase (AS)
• Argininosuccinate Lyase (AL or ASA Lyase)
• Arginase (AG)
• Urea Cycle Disorders Treatment Market, By Treatment Type:
• Amino Acid Formulas
• Phenylbutyrate
• Sodium Benzoate
• Others
• Urea Cycle Disorders Treatment Market, By Route of Administration:
• Oral
• Intravenous
• Urea Cycle Disorders Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Urea Cycle Disorders Treatment Market, By Region:
• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• Europe & CIS
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Urea Cycle Disorders Treatment Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL UREA CYCLE DISORDERS TREATMENT MARKET

4. VOICE OF CUSTOMER

5. EXECUTIVE SUMMARY

6. GLOBAL UREA CYCLE DISORDERS TREATMENT MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
  6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
  6.2.3. By Route of Administration (Oral v/s Intravenous)
  6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  6.2.5. By Company (2021)
  6.2.6. By Region
6.3. Market Map

7. NORTH AMERICA UREA CYCLE DISORDERS TREATMENT MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Enzyme Deficiency Type
  7.2.2. By Treatment Type
  7.2.3. By Route of Administration
  7.2.4. By Distribution Channel
  7.2.5. By Country
7.3. North America: Country Analysis
  7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Enzyme Deficiency Type
      7.3.1.2.2. By Treatment Type
      7.3.1.2.3. By Route of Administration
      7.3.1.2.4. By Distribution Channel
  7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Enzyme Deficiency Type
      7.3.2.2.2. By Treatment Type
      7.3.2.2.3. By Route of Administration
      7.3.2.2.4. By Distribution Channel
  7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Enzyme Deficiency Type
      7.3.3.2.2. By Treatment Type
      7.3.3.2.3. By Route of Administration
      7.3.3.2.4. By Distribution Channel

8. EUROPE UREA CYCLE DISORDERS TREATMENT MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Enzyme Deficiency Type
  8.2.2. By Treatment Type
  8.2.3. By Route of Administration
  8.2.4. By Distribution Channel
  8.2.5. By Country
8.3. Europe: Country Analysis
  8.3.1. France Urea Cycle Disorders Treatment Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Enzyme Deficiency Type
      8.3.1.2.2. By Treatment Type
      8.3.1.2.3. By Route of Administration
      8.3.1.2.4. By Distribution Channel
  8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Enzyme Deficiency Type
      8.3.2.2.2. By Treatment Type
      8.3.2.2.3. By Route of Administration
      8.3.2.2.4. By Distribution Channel
  8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Enzyme Deficiency Type
      8.3.3.2.2. By Treatment Type
      8.3.3.2.3. By Route of Administration
      8.3.3.2.4. By Distribution Channel
  8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Enzyme Deficiency Type
      8.3.4.2.2. By Treatment Type
      8.3.4.2.3. By Route of Administration
      8.3.4.2.4. By Distribution Channel
  8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Enzyme Deficiency Type
      8.3.5.2.2. By Treatment Type
      8.3.5.2.3. By Route of Administration
      8.3.5.2.4. By Distribution Channel

9. ASIA-PACIFIC UREA CYCLE DISORDERS TREATMENT MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Enzyme Deficiency Type
  9.2.2. By Treatment Type
  9.2.3. By Route of Administration
  9.2.4. By Distribution Channel
  9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
  9.3.1. China Urea Cycle Disorders Treatment Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Enzyme Deficiency Type
      9.3.1.2.2. By Treatment Type
      9.3.1.2.3. By Route of Administration
      9.3.1.2.4. By Distribution Channel
  9.3.2. India Urea Cycle Disorders Treatment Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Enzyme Deficiency Type
      9.3.2.2.2. By Treatment Type
      9.3.2.2.3. By Route of Administration
      9.3.2.2.4. By Distribution Channel
  9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Enzyme Deficiency Type
      9.3.3.2.2. By Treatment Type
      9.3.3.2.3. By Route of Administration
      9.3.3.2.4. By Distribution Channel
  9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
    9.3.4.1. Market Size & Forecast
      9.3.4.1.1. By Value
    9.3.4.2. Market Share & Forecast
      9.3.4.2.1. By Enzyme Deficiency Type
      9.3.4.2.2. By Treatment Type
      9.3.4.2.3. By Route of Administration
      9.3.4.2.4. By Distribution Channel
  9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
    9.3.5.1. Market Size & Forecast
      9.3.5.1.1. By Value
    9.3.5.2. Market Share & Forecast
      9.3.5.2.1. By Enzyme Deficiency Type
      9.3.5.2.2. By Treatment Type
      9.3.5.2.3. By Route of Administration
      9.3.5.2.4. By Distribution Channel

10. SOUTH AMERICA UREA CYCLE DISORDERS TREATMENT MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Enzyme Deficiency Type
  10.2.2. By Treatment Type
  10.2.3. By Route of Administration
  10.2.4. By Distribution Channel
  10.2.5. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Enzyme Deficiency Type
      10.3.1.2.2. By Treatment Type
      10.3.1.2.3. By Route of Administration
      10.3.1.2.4. By Distribution Channel
  10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Enzyme Deficiency Type
      10.3.2.2.2. By Treatment Type
      10.3.2.2.3. By Route of Administration
      10.3.2.2.4. By Distribution Channel
  10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Enzyme Deficiency Type
      10.3.3.2.2. By Treatment Type
      10.3.3.2.3. By Route of Administration
      10.3.3.2.4. By Distribution Channel

11. MIDDLE EAST AND AFRICA UREA CYCLE DISORDERS TREATMENT MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Enzyme Deficiency Type
  11.2.2. By Treatment Type
  11.2.3. By Route of Administration
  11.2.4. By Distribution Channel
  11.2.5. By Country
11.3. MEA: Country Analysis
  11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Enzyme Deficiency Type
      11.3.1.2.2. By Treatment Type
      11.3.1.2.3. By Route of Administration
      11.3.1.2.4. By Distribution Channel
  11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Enzyme Deficiency Type
      11.3.2.2.2. By Treatment Type
      11.3.2.2.3. By Route of Administration
      11.3.2.2.4. By Distribution Channel
  11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Enzyme Deficiency Type
      11.3.3.2.2. By Treatment Type
      11.3.3.2.3. By Route of Administration
      11.3.3.2.4. By Distribution Channel

12. MARKET DYNAMICS

12.1. Drivers
12.2. Challenges

13. MARKET TRENDS & DEVELOPMENTS

14. COMPETITIVE LANDSCAPE

14.1. Bausch Health Companies Inc.
14.2. Recordati Rare Diseases
14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
14.4. Acer Therapeutics
14.5. Ultragenyx Pharmaceutical
14.6. Aeglea BioTherapeutics
14.7. Arcturus Therapeutics, Inc.
14.8. Orpharma Pty Ltd.
14.9. Selecta Biosciences, Inc
14.10. Abbott Laboratories, Inc.

15. STRATEGIC RECOMMENDATIONS